Evidence-based articles covering everything Indian patients need to know about GLP-1 medications.
With the 2026 launch of affordable generics, millions more Indians are starting GLP-1s. Here is the updated safety profile, including new Ministry of Health warnings.
Tirzepatide has officially landed for both diabetes and weight loss in India. Here is the updated 2026 data on costs, brands, and clinical outcomes.
With the 2026 patent expiry, semaglutide access in India has been revolutionized. We cover the new generic launches, official pricing, and legal access.
For decades, Indians treated weight loss as a test of character. In 2026, the science of GLP-1 is proving that the struggle is biological, not moral.